Avalyn Pharma Inc.
AVLN
$38.74
$2.165.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 6.56M | 5.02M | 3.90M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 31.29M | 27.91M | 21.78M | ||
| Operating Income | -31.29M | -27.91M | -21.78M | ||
| Income Before Tax | -28.94M | -26.87M | -20.19M | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -28.94M | -26.87M | -20.19M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -28.94M | -26.87M | -20.19M | ||
| EBIT | -31.29M | -27.91M | -21.78M | ||
| EBITDA | -31.18M | -27.85M | -21.77M | ||
| EPS Basic | -0.98 | -21.83 | -17.63 | ||
| Normalized Basic EPS | -0.61 | -13.65 | -11.02 | ||
| EPS Diluted | -0.98 | -21.83 | -17.63 | ||
| Normalized Diluted EPS | -0.61 | -13.65 | -11.02 | ||
| Average Basic Shares Outstanding | 29.65M | 1.23M | 1.15M | ||
| Average Diluted Shares Outstanding | 29.65M | 1.23M | 1.15M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||